Poolbeg Pharma wins UK regulatory clearance for cancer immunotherapy trial

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has received clinical trial authorisation from the UK Medicines and Healthcare products Regulatory Agency for its TOPICAL trial, with interim data expected this summer. The trial is investigating POLB 001, which is being developed as a potential first-approved preventative therapy for cytokine release syndrome (CRS), a serious immune reaction triggered by cancer immunotherapies, including CAR T-cell therapies and bispecific antibodies.